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Fetal hydrops, fetal pleural effusions, hydrothorax, and chylo-
thorax, may be associated with various genetic disorders, in
particularwith theNoonan, cardio-facio-cutaneous andCostello
syndromes. These syndromes, collectively called RASopathies,
are caused by mutations in the RAS/MAPK pathway, which is
known to play a major role in lymphangiogenesis. Recently,
germline mutations in the Casitas B-cell lymphoma (CBL) gene
were reported in 25 patients and of these, 20 had juvenile
myelomonocytic leukemia (JMML). The disorder was named
“CBL syndrome” or “Noonan syndrome-like disorder with or
without juvenile myelomonocytic leukemia” (NSLL). To date,
prenatal abnormalities have not been reported and it is still
debated whether the CBL syndrome falls into the category of a
RASopathy, or represents a different entity. Here we report on
three unrelated patients with CBL mutations manifesting with
hydrops fetalis, fetal pleural effusions and/or congenital hydro-/
chylothorax. Our findings further connect the CBL syndrome
with the RASopathies.  2014 Wiley Periodicals, Inc.
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INTRODUCTION
Noonan syndrome (NS) is a genetically heterogeneous disorder
characterized by short stature, congenital heart defects, characteris-
tic facial features, and variable developmental delay. Several genes
encoding components and modulators of the RAS/MAPK pathway
havebeen shown to causeNSand relateddisorders collectively called
RASopathies [Zenker, 2011]. In 2010, heterozygous germlinemuta-
tionsof theCasitasB-cell lymphoma(CBL) genewere independently
discovered in individuals with features of NSwho had nomutations
in previously known disease genes [Martinelli et al., 2010], and
among patients with juvenile myelomonocytic leukemia (JMML),
some of which displayed congenital anomalies of the RASopathy
spectrum [Perez et al., 2010; Niemeyer et al., 2010]. Clinical features
of the CBL mutation-associated disorder included short stature,
facial dysmorphism, hyperpigmented nevi, pterygium colli, cardio-
vascular abnormalities, pectus excavatum, joint laxity, cubitus
valgus, neonatal feeding problems, and attention deficit hyperactiv-
ity disorder [Perez et al., 2010;Martinelli et al., 2010]. Some patients
also had abnormalities suggesting an underlying vasculopathy, such
as childhood-onset arterial hypertension, acquired cardiomyopa-
thy, and Takayasu arteriitis in one case [Niemeyer et al., 2010].
As a commonmolecular pathophysiology,mutations causative for
the RASopathies have been shown to hyperactivate or dysregulate the
RAS/MAPK pathway signaling. The same appears to be true for
germlineCBLmutationswhich are suggested to act through impaired
receptor ubiquitylation leading to dysregulated signaling through
RAS [Martinelli et al., 2010]. The new syndrome was designated
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Noonan syndrome-like disorder with or without juvenile myelomo-
nocytic leukemia (NSLL) or CBL syndrome (OMIM 613563).
Congenital chylothorax is an uncommon disorder (incidence
1/10,000–15,000 births) and the most common cause of pleural
effusions in newborns [Ferna´ndez Alvarez et al., 1999]. The accu-
mulation of lymphatic fluid that becomes milky after the onset of
enteral nutrition is thought to result from abnormal lymphatic
vessel development. Effusions often resolve with adequate treat-
ment in the first weeks or months. In the majority of cases the
etiology remains unknown. Congenital chylothorax was previously
described with chromosomal conditions including the Down
[Hamada et al., 1992 Turan et al., 2001; Manghat et al., 2004;
Kabbani et al., 2005] and Turner syndromes [Moerman
et al., 1993], and with Mendelian disorders including the Dia-
mond–Blackfan [Lazarus and McCurdy, 1984], Adams–Oliver
[Farrell et al., 1993], Noonan [Prasad et al., 2002; Chen
et al., 2009], and Opitz G/BBB syndromes [Funke et al., 2006].
Fetal chylothoraxmayprogress tohydrops fetalis,whichmay reflect
a more generalized lymphatic dysplasia.
Here we report on three patients withCBLmutations, who had a
pre- and post-natal hydro-/chylothorax and/or hydrops, thus
expanding the clinical phenotype of the NSLL/CBL syndrome
and further highlighting the phenotypic overlap with the other
RASopathies.
CLINICAL REPORTS
Patient 1
Patient 1 (Fig. 1A–C) was born to a healthy 35-year old G1 P1
and a nonconsanguineous 36-year old father. Family history
was unremarkable. Data on nuchal translucency were not
available. Fetal pleural effusions were noted at 21 weeks of
gestation. There was no evidence of an infectious cause. Intrauter-
ine transfusion was performed due to a suspected fetal anemia,
mildly increasing the hemoglobin from 13.9 to 15.1 g/dl (reference
range: 12–18 g/dl). The hydrothorax did not improve and at
week 27, pleural effusionswere relieved by bilateral thoracocentesis.
At 31þ 5 weeks of gestation, placental insufficiency necessitated
premature delivery. Birth weight was 1,410 g (10–25th centile),
length 39 cm (10–25th centile), and occipitofrontal circumference
(OFC) 29.5 cm (10th centile). Grade 4 respiratory distress syn-
drome, grade 1 intraventricular hemorrhage and supravalvular
pulmonary stenosis were diagnosed. By thoracocentesis, a milky
fluid was obtained and a chylothorax was diagnosed. She remained
critically ill during her first 6 months of life. The chylothorax
was drained three times and she was fed with medium chain
triglyceride (MCT) diet. At age 6 months, her length was 57 cm
(3.9 SD) and weight 3,410 g (5.3 SD). The pleura was adhered
using OK-432 (Picibanil1) and thereafter the effusions did not
recur. At age 9 months the chylothorax had completely resolved.
Subsequently her condition gradually improved. Development
was severely delayed. She started to walk at age 35 months.
Neuropediatric evaluation at 3 years indicated a developmental
age of 121/2 months, but then her general condition and develop-
ment improved. She was first seen by a clinical geneticist (O.B.) at
age 31/2 years.
Body height was 98 cm (25–50th centile), weight was 12 kg (3–
10th centile), and OFC was 47 cm (3rd centile). She had thin and
sparse hair, high forehead, hypertelorism, mild ptosis, downslant-
ing palpebral fissures, and low-set ears (Fig. 1A–C). She also had
esotropia, astigmatism, and hyperopia corrected by glasses. She
used two-word-sentences. Her gait was broad-based and unsteady
but she could walk safely with bilateral ankle ortheses. Ultrasound
showed mild supravalvular pulmonary stenosis, mild splenomega-
ly, cholecystolithiasis, and bilateral hip dysplasia. At 51/4 years she
began to use three-word-sentences, but could not hop and jump or
perform a “one-leg-stand”. Height was 109 cm (25th centile),
weight was 17 kg (10–25th centile), and OFC was 48.5 cm (3rd
centile).When last seen at age 6 years, she had severe hypotonia and
strabismus.Her spleenwas enlarged and palpable 3–4 cmbelow the
coastal arch. She consistently wore compression stockings for
lymphedemaof the legs. There had beenno swelling of her genitalia.
Her hip dysplasia was re-evaluated; the left leg was found to be
mildly shorter and osteotomy was postponed due to the chronic
lymphedema. She had made major progresses in development,
could walk stairs, could ride a bike with training wheels, and had
begun speaking in whole sentences, naming colors, and counting.
FIG. 1. (A–C) Female Patient 1 at age 31/2 years; note (A) high
forehead, hypertelorism, and ptosis, (B) low-set ears, and
(C) downslanting palpebral fissures. (D–F) Male Patient 3 at
age 5 months, note (D) prominent forehead and downslanting
palpebral fissures, (E) low-set ears, (F) pectus excavatum and
prominent abdomen.
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Physio-, ergo-, and speech therapies were continued and primary
school enrollment was postponed for a year.
Amniocentesis and karyotyping at age three months had been
normal. At age 31/2 years, her congenital chylothorax, pulmonary
stenosis and facial appearance were considered suggestive of a
RASopathy. Using blood DNA, molecular, molecular genetic anal-
ysis of PTPN11, SOS1, RAF1, KRAS, NRAS, SHOC2, and CBL was
performed showing a de novo mutation c.1100A>C (predicting p.
Q367P) in CBL exon 8 (Fig. 2A). The germline nature of the
mutation was confirmed by testing a saliva sample.
Patient 2
Patient 2wasbornwithout complications at 36weeks of gestation to
unrelated Europeanparents,which apart frommaternalC1 esterase
deficiency were healthy. Fetal ultrasound had showed a left-sided
hydrothorax, mild skin edema, and ascites (hydrops fetalis), as well
as hepatosplenomegaly and polyhydramnios without evidence
for infectious, toxic or immune-mediated disease. Data on
nuchal translucency were not available. Birth weight was 3,165 g
(75–90th centile), length 50 cm (50–75th centile), andOFC34.5 cm
(50–75th centile). Apgar scores were 31, 65 and umbilical pH was
7.20. Due to cyanosis he received bag ventilation and was intubated
after 15min. At the same time the left sided hydrothorax was
punctured with placement of drainage. At age 3weeks, the drainage
was removed, and the hydrothorax did not recur. Echocardiogra-
phy at age 4 weeks revealed mild valvular pulmonary stenosis.
Testes were descended but showedmild hydroceles. Torticollis and
feeding problems were noted neonatally and treated with physio-
therapy and gastric tube feeding followed by gastrostomy tube
insertion until age 4 years. Despite the clinical diagnosis of Noonan
syndrome, extensivemetabolicwork-upandbonemarrowcytology
were performed at age 1 year due to persisting splenomegaly,
frequent infections, generalized muscular hypotonia, failure to
thrive and significant psychomotor retardation, and showed no
abnormalities. Since age 1, length and weight were below the 3rd
centile, with relative macrocephaly. Sitting age was 21 months,
walking agewas three years and he spoke single words at age 2 years.
Cranial MRI with proton spectroscopy at age 2 affirmed some
expansion of subarachnoid spaces, delayed myelinisation and
hypoplasia of olfactory bulbs and optic chiasm, and normal results
of spectroscopy. At age 4, a myopathy was assumed due to severe
muscular hypotonia, diminished strength, reduced muscle mass,
and Gower’s sign. At age 7, persisting splenomegaly, long-lasting
FIG. 2. (A–C) Electropherograms of Patients 1, 2, and 3, respectively. Note identical heterozygous CBL mutations c.1100A>C in Patients 1
and 3 and splice site mutation c.1096–1G>T in Patient 2. (D) Locations of 15 CBL mutations in 28 unrelated patients with NSLL with or
without JMML. Mutations identified in this study, Q367P (Patients 1 and 3) and 1096–1G>T (Patient 2) are shown in bold. Exons are
numbered and drawn to scale; introns and UTRs are not drawn to scale. Note that all mutations alter exons 8–9, corresponding to the linker
and RING finger (RF) domains.
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and easy bruising lead to the diagnoses of immunoglobulin-re-
sponsive thrombocytopenia, diminished factors II, IX, X, and XII,
and microcytic hypochromic anemia. C1 esterase deficiency was
excluded.
At age 7, 10 months weight was 18.3 kg (2nd centile), height
118.4 cm (4th centile), and OFC 50.7 cm (6th centile). He had
bilateral ptosis, downslanting palpebral fissures, hypertelorism,
epicanthal folds, lateral flaring eyebrows, low-set backwards rotated
ears, low posterior hair line, asymmetric ear lengths, and a general
hypotonic expression. He also had broad thorax, mild pectus
excavatum and carinatum, bilateral pes planovalgus, low muscle
mass, broad low-set thumbs, bilateral single palmar crease, fetal
pads, and broad first toes. His knees and lower legs were hyperpig-
mented. At age 11, he was treated with corticosteroids and tra-
nexamic acid for persistent splenomegaly, frequent epistaxis, and
spontaneous bleedings. Lymphedema of the lower limbs had never
been observed.He attended a regular school with special education,
was able to read andwrite, but could not ride a bike or jump on one
foot. He had a pleasant nature and good social interactions.
As his symptoms and facial appearance were suggestive of a
RASopathy, molecular genetic analysis of PTPN11, SOS1, RAF1,
NRAS, BRAF,MEK1,MEK2, andCBLwas performed showing a de
novoCBLmutation c.1096–1G>Tat the splice acceptor site of exon
8 (Fig. 2B). No DNA from saliva or buccal mucosa was available to
confirm the germline origin of the mutation.
Patient 3
Patient 3 (Fig. 1D–F) is the second child of nonconsanguineous
parents. Nuchal translucencymeasurement at 12weekswas normal
(1.3mm), but the pregnancy was subsequently complicated by
polyhydramnios. Moderate fetal hydrops and bilateral pleural
effusions, worse on the right, and accompanied by mediastinal
shift, were identified at 31 weeks gestation, necessitating premature
delivery. Hemoglobin at birth was 18 g/dl (reference range: 13.5–
23 g/dl), suggesting that the fetal hydrops had not been caused by
fetal anemia. Birth parameters were weight 2,190 g (90th centile),
length 42 cm (50th centile), and head circumference 30.5 cm (50–
90th centile). Postnatally, an atrial septal defect (ASD), right
inguinal hernia, bilateral undescended testes, and hepatospleno-
megaly were detected. A blood smear at age 3 weeks showed
monocytosis, and bone marrow aspirate was indicative of
JMML. Renal ultrasound and coagulation studies were normal.
At 7 months of age feeding was exclusively via naso-jejunal tube
(NJT) due to severe feeding difficulties and gastro-esophageal
reflux. He had an ongoing oxygen requirement despite the resolu-
tion of pleural effusions and hydrops. Bilateral lung opacities were
identified on chest radiograph, and lung biopsy showed features of
lymphangiectasia. When assessed at 17 months old, he was able to
sit with support, and rolled inconsistently. He banged objects
together, waved, and babbled but did not have any recognizable
words. When reviewed at 20 months of age, his weight was 9.6 kg
(10–30th centile), length was 77 cm (<3rd centile) and head
circumference was 46 cm (10th centile). He had prominent fore-
head, downslanting palpebral fissures, low-set ears, and pectus
excavatum(Fig. 1D–F). Therewashypotonia andmotormilestones
were delayed. He is on continuous feeds via a percutaneous
gastrostomy (PEG) and still has an ongoing oxygen requirement.
There had been no lymphedema of the lower limbs.
SNP microarray and PTPN11 sequencing returned normal
results. CBL sequencing showed a de novo missense mutation
c.1100A>C (predicting p.Q367P) (Fig. 2C). The germline nature
of the mutation was confirmed by testing a buccal swab sample.
DISCUSSION
Herein we report on three patients, who were screened for muta-
tions in several RAS/MAPK pathway genes because of the clinical
suspicion of a RASopathy and were found to carry de novo
mutations in the CBL gene. CBL mutations have been described
as somatic mutations in various leukemias [Loh et al., 2009;
Schnittger et al., 2012] and as germline mutations in patients
showing variable developmental abnormalities with or without
JMML. Most of the CBLmutations found as germline and somatic
events are located in the linker and ringfingerdomain (RF) encoded
by exons 7–9 [Schnittger et al., 2012] (Fig. 2D). Patients 1 and 3 had
an identical mutation in exon 8, c.1100A>C (p.Q367P), which had
been previously identified in a patient with developmental delay,
cafe-au-lait macules, enlarged left atrium, and transient chaotic
ventricular dysrhythmias [Martinelli et al., 2010] and in a patient
with primary lymphedema and teratoma [Hanson et al., 2014]. The
mutation detected in Patient 2 (c.1096–1G>T) was similarly
described (c.1096–1G>C) in a patient with developmental delay,
cryptorchidism, juvenile xanthogranuloma (JXG), and JMML
[Niemeyer et al., 2010].
Thepresent patients all had craniofacial features compatiblewith
aNoonan-like syndrome, including congenital heart defects typical
of RASopathies, short stature, and delayed development. We
assume that perinatal complications and/or JMML may have
contributed to their developmental delay. Only 14 (56%) of the
25 previously reported NSLL patients were diagnosed with devel-
opmental delay (Table I); 11 patients showed normal development
and in one girl with developmental delay in childhood had caught
up at age 15 years [Martinelli et al., 2010].
It has been increasingly recognized that theRAS-MAPKpathway
plays a major role in the signaling of lymphangiogenesis [Coso
et al., 2014]. Remarkably, our patients all had a history of prenatal
pleural effusions, congenital hydro-/chylothorax, and/or hydrops
fetalis. While such complications have not previously been de-
scribed in individuals with CBL germlinemutations, they belong to
a spectrum of prenatal abnormalities that are typically associated
with the RASopathies. The most frequent prenatal findings in
Noonan syndrome and related disorders include increased nuchal
translucency and cystic hygroma, but pleural effusions, hydrops,
and lymphedema have also been reported [Witt et al., 1987;Witters
et al., 2002; Yoshida et al., 2004; Baldassarre et al., 2011]. These
abnormalitiesmay be regarded as a continuous spectrum caused by
impaired fetal lymphatic drainage probably related to lymphatic
dysplasia or delayed maturation of lymphatic vessels. The lymph-
edema of the feet and legs in Patient 1 and in another patient with
the same c.1100A>C mutation [Hanson et al., 2014] points to an
underlying abnormality of the lymphatic system [Witt et al., 1987;
Roberts et al., 2013] and further documents the pathophysiological
relationship of the CBL syndrome with the Rasopathies. Sponta-
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neous resolution is common, but in some cases lymphedema and
lymphatic/chylous effusionsmay persist until and beyond birth. As
the outcome of fetal hydrops is generally poor, Witters et al. [2002]
found it noteworthy that in a patient with Noonan syndrome,
hydrops resolved spontaneously.However, theoutcomeofNoonan
syndrome-related hydrops is not always favourable and lethality of
Noonan syndrome-associated hydrops, particularly intrauterine
lethality,may be largely underestimated [Yoshida et al., 2004; Lee at
al., 2009]. Recently, a patient with hydrops fetalis, severe ascites,
pleural effusion, and the p.S2G SHOC2 mutation was described
[Gargano et al., 2014]. He died two days after he was born at 30 5/7
weeks gestation due to the severity of his symptoms. Previously
described patients with a CBL germline mutation were selected
either through theirNoonan-like features or throughbeing affected
by JMML. Taking these cohorts together, it can be concluded that
the clinical phenotype associated with CBL mutations generally
includes developmental and physical abnormalities that overlap
with Noonan syndrome or the RASopathy pattern of anomalies
[Perez et al., 2010; Martinelli et al., 2010; Niemeyer et al., 2010;
Digilio et al., 2011].
This is in line with the experimental findings showing that the
mutated protein has a similar effect on the RAS/MAPK pathway as
Noonan syndrome-associated mutations. However, it is likewise
apparent that theNoonan-like features aremore variable, andnot all
patientswouldbeclassifiedashavingNoonan syndromeonaclinical
basis alone. Therefore, it was debatedwhether this syndrome should
be classified as Noonan-like or rather as a distinct “CBL syndrome”.
The clinical observations presented here further support the simi-
larities between the CBL mutation-associated syndrome and
Noonan syndrome, as we can document that these conditions
also share a typical (albeit not specific) pattern of prenatal abnor-
malities. It is obvious that at least part of the typical craniofacial
phenotypeofNoonan syndrome (e.g., pterygiumcolli, lowposterior
hairline, and low-set ears) is the consequenceof a fetalnuchal edema.
Lastnot least, thepresented casesunderline thatCBLmutationshave
to be included in the differential diagnosis of fetal pleural effusions,
hydrops fetalis, and probably also fetal nuchal edema.
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